Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program-Reference-Cited by-同舟云学术

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Published:2013-03-28 Issue:8 Volume:60 Page:1325-1332
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Kolb E. Anders¹,Gorlick Richard²,Reynolds C. Patrick³,Kang Min H.³,Carol Hernan⁴,Lock Richard⁴,Keir Stephen T.⁵,Maris John M.⁶,Billups Catherine A.⁷,DesJardins Christopher⁸,Kurmasheva Raushan T.⁹,Houghton Peter J.⁹,Smith Malcolm A.¹⁰

Affiliation:

1. A.I. duPont Hospital for Children; Wilmington, Delaware

2. The Children's Hospital at Montefiore; Bronx, New York

3. Texas Tech University Health Sciences Center; Lubbock, Texas

4. Children's Cancer Institute Australia for Medical Research; Randwick, New South Wales; Australia

5. Duke University Medical Center; Durham, North Carolina

6. Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute; Philadelphia, Pennsylvania

7. St. Jude Children's Research Hospital; Memphis, Tennessee

8. Eisai, Inc.; Andover, Massachusetts

9. Nationwide Children's Hospital; Columbus, Ohio

10. Cancer Therapy Evaluation Program; NCI; Bethesda, Maryland

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference42 articles.

1. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data;Bai;J Biol Chem,1991

2. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B;Towle;Cancer Res,2001

3. Microtubules as a target for anticancer drugs;Jordan;Nat Rev Cancer,2004

4. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability;Smith;Biochemistry,2010

5. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth;Jordan;Mol Cancer Ther,2005

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis of 11C-Radiolabeled Eribulin as a Companion Diagnostics PET Tracer for Brain Glioblastoma;Bulletin of the Chemical Society of Japan;2023-03

2. Marine Antineoplastic Templates: Clinical trials (I-III) and Motifs Carried via Antibodies to Target Specific Cancerous Tissues;Biomedical and Pharmacology Journal;2022-06-30

3. Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study;BMC Cancer;2022-05-11

4. In vitro radiosensitization by eribulin in human cancer cell lines;Reports of Practical Oncology and Radiotherapy;2022-04-07

5. Regulated cell death and drug resistance in malignant bone tumors;Bone Cancer;2022